Serum and urine N-acetyl-beta-D-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin dependent diabetics.
N-Acetyl-beta-D-glucosaminidase (NAG) activity has been measured in the serum and urine of diabetics. Results have shown significantly higher levels of serum NAG in newly diagnosed diabetics (945 +/- 372 units/ml) compared to non-diabetic controll (668 +/- 225, p less than 0.005) and the levels were reduced by treatment (778 +/- 218, p less than 0.05). Changes occurred in the same direction when urinary NAG was measured falling from a mean of 572 +/- 298 units/mg urinary creatinine, on diagnosis to 291 +/- 176 after treatment (p less than 0.005), as compared with 177 +/- 86 in non-diabetic controls. Established insulin-treated diabetics had a urinary NAG activity of 461 +/- 440 and a serum NAG activity of 790 +/- 245. No correlation was found between urine NAG activity and urine glucose (r = 0.315), or serum NAG and serum glucose (r = 0.273). An assessment of this enzyme is made in relation to early microangiopathy.
D000118:Acetylglucosaminidase / Q000097:blood / Q000378:metabolism* / Q000652:urine; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology*; D006596:Hexosaminidases / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use
D007328:Insulin; D006596:Hexosaminidases; D000118:Acetylglucosaminidase